Clinical Trials

Metastatic Castration-resistant Prostate Neoplasms

NCT06863272 2026-04-13

IDeate-Prostate02

360 enrolled

Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant

NCT06925737 2026-04-13

MK-2400-001

1,440 enrolled

Prostatic Neoplasms

NCT07419295 2026-04-13

TroFuse-031

590 enrolled

Urinary Bladder Neoplasms

NCT07287150 2026-04-08

InavoPC

Phase 2 Recruiting

100 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT07344779 2026-04-03

ROAD

Active not recruiting

1,600 enrolled

Prostatic Neoplasms

NCT06353386 2026-03-24

MK-5684-01A

220 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT06661122 2026-03-19

HAYATE

Recruiting

100 enrolled

Phase 2 Active not recruiting

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT05848011 2026-03-16

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

154 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT06545955 2026-03-04

ABLE-22

250 enrolled

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

NCT06551324 2026-03-04

MEVPRO-1

600 enrolled

Prostatic Neoplasms, Recurrence

NCT02861573 2026-02-17

KEYNOTE-365

1,200 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT05701007 2026-01-29

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

1,083 enrolled 29 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT06764485 2026-01-28

rechARge

960 enrolled

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT03338790 2026-01-27

CheckMate 9KD

Phase 2 Completed

292 enrolled 21 charts

Phase 3 Not yet recruiting

Prostatic Neoplasms

NCT07365995 2026-01-26

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

736 enrolled

BreastGenitourinaryHead & NeckThoracic

Metastatic Castration-resistant Prostate Cancer

NCT07358806 2026-01-22

Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors

Phase 1 Recruiting

51 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Prostatic Neoplasms

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Phase 2 Active not recruiting

40 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

608 enrolled 22 charts 2 FDA

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT06568094 2025-12-31

A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

100 enrolled

Prostatic Neoplasms

NCT04034095 2025-12-15

A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan

979 enrolled

Prostatic Neoplasms

NCT02799602 2025-12-04

ARASENS

1,306 enrolled 25 charts 5 FDA

Phase 1 Active not recruiting

Metastatic Hormone-sensitive Prostate Cancer

NCT00600496 2025-11-13

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

140 enrolled

BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT06857175 2025-09-12

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma

508 enrolled

Carcinoma, Transitional Cell

NCT04666129 2025-08-17

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Phase 1 Completed

48 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Metastatic Castration-Resistant Prostate Cancer

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

613 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT06632951 2025-08-11

LIVIGNO-3

Phase 2 Active not recruiting

150 enrolled

Carcinoma, Transitional Cell, Neoplasms

NCT04527991 2025-08-03

TROPiCS-04

712 enrolled

GastrointestinalGenitourinaryThoracic

Locally Advanced or Metastatic Unresectable Urothelial Cancer

NCT04306900 2025-07-29

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

Phase 1 Completed

185 enrolled 28 charts

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02975934 2025-07-25

TRITON3

405 enrolled 34 charts 3 FDA

Metastatic Castration Resistant Prostate Cancer

NCT04381832 2025-07-22

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Phase 1/2 Completed

173 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT03834506 2025-07-18

KEYNOTE-921

1,030 enrolled 24 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT05005728 2025-07-17

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

72 enrolled

Prostatic Neoplasms

NCT06520345 2025-07-10

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

430 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Prostatic Neoplasms

NCT06769425 2025-06-24

HS-10502

Phase 1 Recruiting

157 enrolled

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT06663137 2025-06-13

HGNMIBC

Phase 2 Recruiting

70 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT04100018 2025-06-12

CheckMate 7DX

1,030 enrolled 25 charts

Prostatic Neoplasms

NCT05169684 2025-06-10

A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

Phase 2 Terminated

10 enrolled 15 charts

Phase 1/2 Active not recruiting

Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant

NCT04140526 2025-05-23

PRESERVE-001

733 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Adenoid Cystic, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT02288247 2025-04-08

PRESIDE

688 enrolled 13 charts

Phase 3 Active not recruiting

Neoplasm Metastasis, Prostatic Neoplasms

NCT05348577 2025-01-27

CAPItello280

1,035 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT06732531 2025-01-09

Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer

48 enrolled

Urinary Bladder Neoplasms

NCT03328364 2024-11-21

A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden

211 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Metastatic Castration Resistant Prostate Cancer

NCT02009449 2024-11-15

IVY

Phase 1 Completed

353 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT06498921 2024-10-24

BELBEQA

106 enrolled